APPILI THERAPEUTICS
Appili Therapeutics is an anti-infective pharmaceutical development company. Our approach lies in matching unmet medical needs with opportunities for more effective solutions that range from improvements in established therapies to entirely new classes of anti-infectives.
APPILI THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2015-01-01
Address:
Halifax, Nova Scotia, Canada
Country:
Canada
Website Url:
http://www.appilitherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(902)442-4655
Total Funding:
63.58 M USD
Technology used in webpage:
Google Maps Person Schema Gravatar Profiles U.S. Server Location
Similar Organizations
APCBio Innovations
APCBio Innovations is a biopharmaceutical product development company.
Arkuda Therapeutics
Arkuda Therapeutics is a pharmaceutical company.
Blade Therapeutics
Blade Therapeutics is a discovery stage drug development company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Current Employees Featured
Yoav Golan Chief Medical Officer @ Appili Therapeutics
Chief Medical Officer
Kimberly Stephens Chief Financial Officer @ Appili Therapeutics
Chief Financial Officer
2016-09-01
Armand Balboni Chief Executive Officer @ Appili Therapeutics
Chief Executive Officer
2020-07-01
Gary Nabors Chief Development Officer @ Appili Therapeutics
Chief Development Officer
2023-04-01
Founder
Stock Details
Investors List
Bloom Burton & Co.
Bloom Burton & Co. investment in Post-IPO Debt - Appili Therapeutics
Bloom Burton & Co.
Bloom Burton & Co. investment in Post-IPO Debt - Appili Therapeutics
Long Zone Holdings
Long Zone Holdings investment in Post-IPO Debt - Appili Therapeutics
Defense Threat Reduction Agency (DTRA)
Defense Threat Reduction Agency (DTRA) investment in Grant - Appili Therapeutics
FUJIFILM Toyama
FUJIFILM Toyama investment in Post-IPO Equity - Appili Therapeutics
The Lind Partners
The Lind Partners investment in Post-IPO Debt - Appili Therapeutics
Industrial Alliance Securities
Industrial Alliance Securities investment in Post-IPO Equity - Appili Therapeutics
Haywood Securities Inc.
Haywood Securities Inc. investment in Post-IPO Equity - Appili Therapeutics
Research Capital Corporation
Research Capital Corporation investment in Post-IPO Equity - Appili Therapeutics
Richardson GMP
Richardson GMP investment in Post-IPO Equity - Appili Therapeutics
Key Employee Changes
Official Site Inspections
http://www.appilitherapeutics.com Semrush global rank: 7.77 M Semrush visits lastest month: 717
- Host name: 195.241.167.72.host.secureserver.net
- IP address: 72.167.241.195
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Appili Therapeutics"
Home - Appili Therapeutics
Appili Therapeutics is a people-focused biopharmaceutical company focused on tackling the serious global challenges in infectious disease and biodefense.See details»
Appili Therapeutics - Crunchbase Company Profile
Organization. Appili Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. …See details»
Appili Therapeutics - LinkedIn
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.See details»
Highlights - Appili Therapeutics
Investors Highlights APPILI THERAPEUTICS In The Global Race Against Infectious Diseases Internal Innovation; Active In-Licensing. Appili Therapeutics is proud to be at the forefront of …See details»
Appili Therapeutics (TSX:APLI) Company Profile & Description
5 days ago Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada.See details»
Appili Therapeutics Reports Financial and Operational
Feb 14, 2025 Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory...See details»
Appili Therapeutics - Craft
Appili Therapeutics has 5 employees across 2 locations and $16.3 m in total funding,. See insights on Appili Therapeutics including office locations, competitors, revenue, financials, …See details»
Appili Therapeutics Announces Submission of U.S. Federal
Mar 18, 2025 Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOutside date …See details»
Appili Therapeutics - 2025 Company Profile - Tracxn
Mar 23, 2025 Developer of drugs to treat infectious diseases. The company's product API-1503 is a class of 30S ribosome targeting agents for Gram-negative bacterias, API-1501 is a …See details»
Contact - Appili Therapeutics
Contact Corporate Headquarters #21-1344 Summer Street Halifax, NS B3H 0A8 Phone number: 902-442-4655 ext 0 Careers Media Contact Corporate Headquarters APPILI THERAPEUTICS …See details»
Appili Therapeutics Inc. (APLIF) Company Profile & Overview
Feb 28, 2025 Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada.See details»
Appili Therapeutics - Overview, News & Similar companies
Apr 2, 2024 Popular Searches Appili Therapeutics Inc Appili Therapeutics Appili Therapeutics - Inc Appilitherapeutics Ati-1501 SIC Code 87,873 NAICS Code 54,541 Ticker OTC: APLIF …See details»
Appili Therapeutics Announces Alignment with FDA on ... - BioSpace
Nov 1, 2024 For more information, visit www.AppiliTherapeutics.com. Forward Looking Statements This news release contains “forward-looking statements”, including with respect to …See details»
Appili Therapeutics Reports Financial and Operational Results for …
Feb 14, 2025 For more information, visit www.AppiliTherapeutics.com. Forward looking statements. This news release contains “forward-looking statements”, including with respect to …See details»
Appili Therapeutics Announces Submission of U.S. Federal
Mar 18, 2025 For more information, visit www.AppiliTherapeutics.com. Forward Looking Statements . This news release contains “forward-looking statements”, including with respect …See details»
Appili President and CEO, Don Cilla to Join Aditxt CEO
Apr 2, 2025 The event will also include a Q&A session, with questions welcomed at info@appilitherapeutics.com. Appili will join additional Aditxt Weekly Updates throughout the …See details»
Appili Therapeutics Reports Financial and Operational Results
Feb 14, 2025 --Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its …See details»
Appili Therapeutics and Colleagues Publish Manuscript on
3 days ago A review of recent findings suggests that Appili’s biodefense vaccine, ATI-1701, may have a role in preventing tularemia outbreaks. May 01, 2025 07:34 ET | Source: Appili …See details»
News - Appili Therapeutics
Feb 14, 2025 info@appilitherapeutics.com Get in Touch NEWS NEWS NEWS NEWS News Highlights Check this page for recent news from Appili Therapeutics. Members of the media …See details»
Pipeline - Appili Therapeutics
PIPELINE Overview Diversified Pipeline Driving Near- And Long-Term Value Through Appili’s unique approach to drug development, we have created a pipeline containing a deliberate mix …See details»